Deutetrabenazine for Huntington Disease

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Huntington Disease
Deutetrabenazine - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will look at whether the drug deutetrabenazine can improve speech and gait in people with movement disorders.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Huntington Disease

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: Up to 10 weeks

Up to 10 Weeks
10 Meter Walk test
Four Square Step Test (FSST)
Up to 10 weeks
3-D optical motion capture system recording
Communication Effectiveness Survey
Functional Gait Assessment (FGA)
Functional Joint Kinematics Improvements
Health Status
Motor Speech Evaluation (MSE)
Nine-Hole Peg Test
Sentence Intelligibility Test (SIT)
The Functional Assessment of Chronic Illness Therapy (FACIT) scale
Unified Huntington's Disease Rating Scale (UHDRS) Chorea Scale

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Huntington Disease

Trial Design

1 Treatment Group

Deutetrabenazine
1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Deutetrabenazine · No Placebo Group · Phase 2 & 3

Deutetrabenazine
Drug
Experimental Group · 1 Intervention: Deutetrabenazine · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Deutetrabenazine
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 10 weeks

Who is running the clinical trial?

Teva Branded Pharmaceutical Products R&D, Inc.Industry Sponsor
242 Previous Clinical Trials
3,482,092 Total Patients Enrolled
4 Trials studying Huntington Disease
1,106 Patients Enrolled for Huntington Disease
Vanderbilt University Medical CenterLead Sponsor
768 Previous Clinical Trials
592,084 Total Patients Enrolled
1 Trials studying Huntington Disease
100 Patients Enrolled for Huntington Disease
Amy E Brown, MDPrincipal Investigator - Vanderbilt University Medical Center
Vanderbilt University Medical Center

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
, study participants were asked to complete a brief questionnaire
I have completed at least 10th grade.
The text states that a Montreal Cognitive Assessment (MOCA) score of ≥22 on screening indicates that a person is not experiencing any signs of cognitive impairment.
Female subjects of childbearing potential agree to use contraception during the study.
, The investigator judges that the person is medically stable enough to be treated as an outpatient.
A person has Huntington's disease if they have a CAG repeat of 37 or more.
The UHDRS total maximal chorea score is ≥ 8.
The patient can now walk 10 meters without assistance.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 8th, 2021

Last Reviewed: October 20th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

How old are they?
18 - 65100.0%
What site did they apply to?
Vanderbilt University Medical Center100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%